Thank you very much.
Thank you to all the panellists for appearing today.
I just wanted to begin by pointing out that in the testimony, Dr. Wong-Rieger, you gave.... I think one of the important pieces to highlight is how important this program is. This is Canada's first-ever strategy for rare diseases. I know Canadians, particularly the Canadians you represent, were very happy to see this.
I would interpret this as complementing pharmacare as part of the package, as it were. Admittedly, it requires some time for implementation. We're all looking forward to that.
I'm going to begin my questions with Ms. Silas.
Ms. Silas, you and I have had many discussions over the last couple of years about pharmacare. Thank you for the socks. On my socks, it says “comprehensive”, “accessible”, “universal”, “portable” and “public”. I understand that—